|Venture Round, 5/2013 |
Neurodegenerative diseases remain unpreventable, incurable, and largely untreatable. Today, diagnosis is typically carried out through psychiatric examination at advanced stages of the disease when the damage is significant and the potential for delaying disease progression is low.
There is an urgent need for rapid, low-cost, accurate diagnostic tests for Alzheimer’s disease (AD) and ALS (Lou Gehrig’s disease) early in their course when therapy is most effective and permits better disease management.
One in eight people over the age of 65 have AD, with over 5.1 million patients in the U.S. Incorporating an accurate diagnostic capable of monitoring disease progression will greatly ease the burden of late-stage diagnosis on families — and the health system. The U.S. Surgeon General and the UK’s NHS recognize this milestone as a top priority in the treatment of Alzheimer’s